Zhou Yue, Chen Jian-jun, Lu Zhong-yuan, Kong Wei-jia
Department of Otorhinolaryngology, Union Hospital of Tongji Medical College of Huazhong University of Science and Technology, Wuhan 430030, China.
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2010 Jan;45(1):52-5.
To investigate the effect of early allergen exposure on later development of allergic rhinitis in mouse.
Twenty-four BALB/c neonates were randomly divided into 4 groups (low-dose group, high-dose group, negative control group and positive control group), each group had 6 mice. The mice were administered ovalbumin (OVA) by subcutaneous injection on day 1, 5, 12 after birth (10 μg OVA in 0.05 ml saline for low-dose group, 1000 μg OVA in 0.05 ml saline for high-dose group, only saline for negative and positive control group). Then the mice were sensitized and intranasally challenged with OVA (saline without OVA was used in negative control group) after 6 weeks. Symptoms, histopathological changes of nasal mucosa were observed, OVA-IgE in serum was examined, cytokines IL-4, IL-5 and IFN-gamma were detected in the supernatant of cultured splenic mononuclear cells.
Compared to the positive control group, symptoms and nasal mucosa histological changes of high-dose group was indistinctive. The level of OVA-IgE and cytokines IL-4, IL-5 (x(-) +/- s) in high-dose group [(265.11 +/- 26.29), (446.39 +/- 72.83) and (171.24 +/- 15.66) pg/ml, respectively] were significantly lower than those in positive control group [(665.85 +/- 43.15), (1113.45 +/- 30.47), (255.36 +/- 30.96) pg/ml, respectively, t value were 0.000, 0.000 and 0.009, respectively, all P < 0.05]. The level of IFN-γ in high-dose group [(319.74 +/- 56.30) pg/ml] was significantly higher than those in positive control group [(170.02 +/- 14.50) pg/ml, t = 0.000, P < 0.05]. There was no significant difference of the results between the low-dose group and positive control group.
Neonatal immunization with high-dose OVA inhibited the future allergic rhinitis symptoms, nasal histological changes, serum OVA-IgE levels and Th1/Th2 cytokine imbalance, resulting in the protective effect.
探讨早期接触变应原对小鼠变应性鼻炎后期发展的影响。
将24只BALB/c新生小鼠随机分为4组（低剂量组、高剂量组、阴性对照组和阳性对照组），每组6只。于出生后第1、5、12天对小鼠进行皮下注射卵清蛋白（OVA）（低剂量组为0.05 ml盐水中含10 μg OVA，高剂量组为0.05 ml盐水中含1000 μg OVA，阴性和阳性对照组仅注射盐水）。6周后，对小鼠进行OVA致敏及鼻内激发（阴性对照组使用不含OVA的盐水）。观察小鼠症状、鼻黏膜组织病理学变化，检测血清中OVA-IgE，检测培养的脾单个核细胞上清液中细胞因子IL-4、IL-5和IFN-γ。
与阳性对照组相比，高剂量组小鼠症状及鼻黏膜组织学变化不明显。高剂量组OVA-IgE及细胞因子IL-4、IL-5水平[分别为(265.11±26.29)、(446.39±72.83)和(171.24±15.66) pg/ml]显著低于阳性对照组[分别为(665.85±43.15)、(1113.45±30.47)、(255.36±30.96) pg/ml，t值分别为0.000、0.000和0.009，均P<0.05]。高剂量组IFN-γ水平[(319.74±56.30) pg/ml]显著高于阳性对照组[(170.02±14.50) pg/ml，t = 0.000，P<0.05]。低剂量组与阳性对照组结果无显著差异。
高剂量OVA对新生小鼠进行免疫可抑制其未来变应性鼻炎症状、鼻组织学变化、血清OVA-IgE水平及Th1/Th2细胞因子失衡，产生保护作用。
